BENEXATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27N3O4
Molecular Weight	409.4782
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=N)NC[C@H]1CC[C@@H](CC1)C(=O)OC2=C(C=CC=C2)C(=O)OCC3=CC=CC=C3

InChI

InChIKey=IAXUQWSLRKIRFR-SAABIXHNSA-N

InChI=1S/C23H27N3O4/c24-23(25)26-14-16-10-12-18(13-11-16)21(27)30-20-9-5-4-8-19(20)22(28)29-15-17-6-2-1-3-7-17/h1-9,16,18H,10-15H2,(H4,24,25,26)/t16-,18-

HIDE SMILES / InChI

Molecular Formula	C23H27N3O4
Molecular Weight	409.4782
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.e-ce.org/upload/pdf/29400520.pdf
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/27446246

Benexate is an active ingredient of benexate.CD or benexate hydrochloride betadex, a beta-cyclodextrin complex. Benexate was approved for the treatment of Gastric Ulcer in Japan. The terapeuthic effect of benexate is associated with promotion of prostaglandin synthesis, inhibition of acid secretion and increase in mucosal blood flow.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23 Target ID: GO:0001516 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27446246	Activator 1447
gastric acid secretion 6 Target ID: GO:0001696 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27446246	Inhibitor 8504
gastric mucosal blood circulation 6 Target ID: GO:1990768 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27446246	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 74 Sources: http://backoffice.phillipcapital.in/Backoffice/Researchfiles/PC_-_Lupin_Co_Udpate_-_Aug_2016_20160802190017.pdf	Primary		Approved 8583	ULGUT Approved Use Unknown
Gastritis 46 Sources: http://backoffice.phillipcapital.in/Backoffice/Researchfiles/PC_-_Lupin_Co_Udpate_-_Aug_2016_20160802190017.pdf	Primary		Approved 8583	ULGUT Approved Use Unknown

PubMed

Title	Date	PubMed
Benexate hydrochloride betadex modulates nitric oxide synthesis and cytokine expression in gastric ulcers.	2016-08	27446246
Differential effect of benexate hydrochloride betadex on prostaglandin levels in stomach and inflammatory site in rats.	1996-10	8912919
In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori.	1996-05	8737142
Syntheses and inhibitory effects on gastric lesions of trans-guanidinomethylcyclohexane carboxylic acid arylamides.	1993-03	8477502

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:33 GMT 2025`
Record UNII	O3PR2X907M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Benexate [WHO-DD]

Preferred Name

English

BENEXATE

Official Name

English

BENZYL SALICYLATE, TRANS-4-(GUANIDINOMETHYL)CYCLOHEXANECARBOXYLATE

Systematic Name

English

benexate [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698